METHYS Dx signs exclusive License Agreement with CNRS Innovation!

🚀METHYS Dx signs exclusive License Agreement with CNRS Innovation for disruptive detection technology!!

🤝We are pleased to announce that METHYS Dx has signed an exclusive license agreement with CNRS Innovation covering three patent families on an ultra-sensitive and disruptive detection technology.

🔬 This technology primarily originates from collaborative work between CNRS and Université de Tokyo, with Yannick Rondelez and Guillaume Gines, co-founders of METHYS Dx, amongst its inventors. Their work led to the development of an innovative amplification technology based on networks of chemical reactions, enabling the detection of single molecules with very high sensitivity.

📄Further developments were then carried out by Yannick and Guillaume, within the Gulliver Laboratory (ESPCI Paris – PSL), who teamed up with Valerie Taly and the MEPPOT laboratory (Université Paris Cité), and resulted in two further patent filings.

🧬Originally developed for micro-RNA detection, METHYS Dx is now developing the technology to detect DNA methylation biomarkers associated with several cancers.

🚀Through this license agreement, METHYS Dx will be able to leverage these technologies to develop a new generation of products for early cancer monitoring, complementing its line of digital PCR-based kits currently commercialized for clinical research.

🎯This milestone marks a new phase for the company, with the ambition to offer services based on automated processes using this technology by 2028, a development which will be funded in part by the currently on-going Seed fundraising round.

👏 We would like to warmly thank CNRS Innovation and the research teams involved for the quality of the discussions and their long-standing collaboration.